Arixa Pharmaceuticals

Arixa Pharmaceuticals, Inc. is focused on developing oral antibiotics to combat drug-resistant Gram-negative infections, addressing a critical healthcare need. The company’s lead product, ARX-1796, is a proprietary oral prodrug of Avibactam, a broad-spectrum beta-lactamase inhibitor that has received FDA approval. Arixa utilizes a unique technology platform that employs innovative prodrug chemistry to transform existing intravenous-only antimicrobial agents into orally administered formulations, facilitating easier patient access to treatment. Founded in 2016 and headquartered in Palo Alto, California, Arixa has successfully navigated the medicinal chemistry challenges associated with developing prodrugs in this antibiotic class and anticipates securing broad patent protection for its compositions.